US 12,168,766 B2
Modulators of APOL1 expression
Susan M. Freier, San Diego, CA (US)
Assigned to ASTRAZENECA AB, Sodertalje (SE)
Filed by Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed on Nov. 8, 2022, as Appl. No. 18/053,447.
Application 18/053,447 is a continuation of application No. 17/025,239, filed on Sep. 18, 2020, granted, now 11,525,136.
Application 17/025,239 is a continuation of application No. 16/418,060, filed on May 21, 2019, granted, now 10,927,377, issued on Feb. 23, 2021.
Claims priority of provisional application 62/674,865, filed on May 22, 2018.
Prior Publication US 2023/0265428 A1, Aug. 24, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/04 (2006.01); A61P 13/02 (2006.01); C12N 15/113 (2010.01)
CPC C12N 15/113 (2013.01) [A61P 13/02 (2018.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2320/32 (2013.01); C12N 2320/35 (2013.01)] 12 Claims
 
1. A method of treating, preventing, or ameliorating a kidney disease associated with APOL1 in an individual comprising administering to the individual a compound according to the following formula (SEQ ID NO: 1950):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, thereby treating, preventing, or ameliorating the disease.